Drug lookup
Drug reference

Tryptophan

Essential amino acid (sleep aid / depression adjunct) · Antidepressant

Also known as L-Tryptophan

START
1–2 g PO at bedtime (insomnia adjunct)
TYPICAL MAX
6 g/day
STOP IF
Eosinophilia/myalgia symptoms or serotonin syndrome
WATCH
Pharmaceutical-grade source; serotonergic co-medication
CDSCO approvedATC N06AX02
Dose laddermg/d
1ksleep3kantidepress6kmax/day
Renal dose adjustmenteGFR mL/min/1.73m²
FULLStandard dosing30CAUTIONCaution — limited data90

KDIGO 2024 + manufacturer label

Pharmacokineticsplasma · t hours
45minONSET2hPEAK1.8h7hDURATION
ONSET
45min · absorption
PEAK
2h · Tmax
1.8h ·
DURATION
7h · per dose
EXCRETION
Renal — kynurenine/5-HTP metabolites
route + CYP
INTERACTIONS
12 major
incl. contraindicated
PREGNANCY
Avoid pharmacologic doses; nutritional intake fine.
FDA category + note
Top interactionssee all 12
  • Mao InhibitorsContraindicatedDatabaseKimi deep-research + Cla
  • MoclobemideSevereTextbookG&G 14e
  • AmitriptylineSevereDatabaseDDInter
  • AmoxapineSevereDatabaseDDInter

Mechanism

Essential amino acid that is precursor to serotonin and melatonin; supplementation modestly raises CNS serotonin synthesis with mild sedative/antidepressant effect; also a niacin (NAD) precursor.

Indications

Adjunct in depression (with antidepressants)Mild sleep disturbance / insomniaAffective disorders (specialist)

Dosing

Adult
1–3 g PO at bedtime for sleep; 3–6 g/day in 3 divided doses for depression adjunct (specialist).
Pediatric
Generally not recommended.
Renal adjustment
Caution in severe renal impairment.
Hepatic adjustment
Avoid in significant hepatic disease.
Geriatric
Lower doses; monitor sedation.
Max dose
6 g/day

Pharmacokinetics

Onset
Sleep effect 30–60 min; mood over weeks
Peak effect
~2 h (Tmax)
Duration
~6–8 h
Half-life
~1.5–2 h
Bioavailability
Well absorbed orally
Protein binding
~85% (albumin)
Metabolism
Hepatic kynurenine pathway and 5-HTP pathway
Excretion
Renal (metabolites)

Contraindications

  • History of eosinophilia-myalgia syndrome (EMS — historical contaminated batches)
  • Severe hepatic / renal impairment
  • Concomitant MAO inhibitors
  • Hypersensitivity

Side effects

Common
NauseaDrowsinessHeadacheLight-headedness
Serious
  • Eosinophilia-myalgia syndrome (1989 epidemic — contaminated source)
  • Serotonin syndrome (with serotonergic drugs)
  • Severe hypersensitivity

Pregnancy & lactation

Pregnancy

Avoid pharmacologic doses; nutritional intake fine.

Lactation

Avoid pharmacologic doses; nutritional intake compatible.

Drug interactions

Mao Inhibitors
Contraindicated
Database

Markedly increased serotonin synthesis + reduced metabolism

Contraindicated

Source: Kimi deep-research + Cla

Moclobemide
Severe
Textbook

Serotonin syndrome, characterized by hyperthermia, muscle rigidity, myoclonus, tremors, autonomic instability, confusion, irritability, and agitation, which can progress to coma and death.

Avoid coadministration.

Source: G&G 14e

Amitriptyline
Severe
Database

Drug interaction classified as: synergy

Source: DDInter

Amoxapine
Severe
Database

Drug interaction classified as: synergy

Source: DDInter

Buspirone
Severe
Database

Drug interaction classified as: synergy

Source: DDInter

Citalopram
Severe
Database

Drug interaction classified as: synergy

Source: DDInter

Clomipramine
Severe
Database

Drug interaction classified as: synergy

Source: DDInter

Cyclobenzaprine
Severe
Database

Clinical effect not specified

Source: DDInter

Desipramine
Severe
Database

Clinical effect not specified

Source: DDInter

Desvenlafaxine
Severe
Database

Clinical effect not specified

Source: DDInter

Dextropropoxyphene
Severe
Database

Clinical effect not specified

Source: DDInter

Dihydroergotamine
Severe
Database

Clinical effect not specified

Source: DDInter

Related guidelines

Ask House about Tryptophan

Continue into a citation-backed clinical answer with the drug context already attached.

Sources: Katzung, BNF, Nelson, Harriet Lane·Verified: 2026-05-20 · House clinical team·Cockpit curated: 2026-05-20